Line 1,529: |
Line 1,529: |
| | | | | |
| |- | | |- |
− | |Aggressive NK-cell Leukemia||Disease|| | + | |Aggressive NK-cell Leukemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD |
− | |
| |
| | | | | |
| | | | | |
| + | |?PENDING |
| | ||SP | | | ||SP |
| | | | | |
Line 1,561: |
Line 1,561: |
| | | | | |
| |- | | |- |
− | | Hydroa Vacciniforme-Like Lymphoproliferative Disorder||Disease|| | + | | Hydroa Vacciniforme-Like Lymphoproliferative Disorder||Disease|| |
| | | | | |
| | | | | |
Line 1,577: |
Line 1,577: |
| | | | | |
| |- | | |- |
− | |Adult T-cell Leukemia/Lymphoma||Disease|| | + | |Adult T-cell Leukemia/Lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG |
− | |
| |
| | | | | |
| | | | | |
| + | |?PENDING |
| | ||SP | | | ||SP |
| | | | | |
Line 1,839: |
Line 1,839: |
| | | | | |
| | | | | |
− | | | + | |PENDING |
| | ||GC | | | ||GC |
| | | | | |